

ANTIMICROBIAL PEPTIDE ISOLATED FROM
HALOCYNTHIA AURANTIUM

FIELD OF THE INVENTION

5 The present invention relates to an antimicrobial peptide isolated from *Halocynthia aurantium*, more particularly, to an antimicrobial peptide isolated from the body fluid of *Halocynthia aurantium* and an antimicrobial agent comprising the same as an active
10 ingredient. The antimicrobial peptide of the present invention shows excellent antimicrobial activity under strong acidic and basic environments. Moreover, it also shows strong antimicrobial activity against resistant bacteria. So, it can be used usefully as a
15 natural antimicrobial agent.

BACKGROUND

Most researchers studying immunology have been interested rather in adaptive immunity having memory
20 and specificity than in innate immunity, so far. Nevertheless, innate immunity plays an important role in self-defense system of animals. For instance, 1) innate immune cells prohibit the invasion of microorganisms through skin or epithelial cells of the
25 intestines, 2) innate immune cells restrain pathogens

invading into blood or body fluid with their phagocytosis, 3) innate immunity preferentially prevents various invading microorganisms from growing in body fluid after infection even before adaptive immunity or phagocytosis is activated since innate immunity does not have specificity. Cells that are responsible for innate immunity use various antimicrobial substances such as simple inorganic compounds (H_2O_2 , NO, etc), antimicrobial peptides and proteins in order to function as the above. Antimicrobial peptides or proteins have been reported to be on mucosal epithelial surface, in body fluid and in intracellular organelles of phagocytes, and to have various sizes, structures and activity (Hancock, R. E. et al., *Proc. Natl. Acad. Sci.*, 2000, 97, 8856-8861). But there are common characteristics, too, that is, most antimicrobial peptides or proteins have complementary positive charge to negative charge of cell membrane of microorganisms, antimicrobial proteins having enzyme activity (proteases or muramidases) hydrolyze the membrane of bacteria and antimicrobial peptides also target in cell membrane of microorganisms (Zhang, L. et al., *J. Biol. Chem.*, 2001, 276, 35714-35722). Owing to these mechanisms, antimicrobial peptides are expected to be very helpful for the development of novel antibiotics that can be

effectively used for the bacteria having resistance against conventional antibiotics. Frequent appearance of resistant strains resulted from overuse of chemical synthetic antibiotics evokes the interest in these antimicrobial peptides as well.

Antimicrobial peptides are largely classified two groups: one group is composed of peptides having bipolar α -helical structure and the other group is composed of peptides having β -sheet structure stabilized by intradisulfide bonds. Cysteine containing antimicrobial peptides mostly keep even number of cysteine residues from 2 to 8, which contribute to build intradisulfide bonds, resulting in the completion of a stable structure. Table 1 shows a classification of antimicrobial peptides having β -sheet structure by the number of cysteine residue in a molecule.

<Table 1>

β -sheet antimicrobial peptides classified by the number of intramolecular cysteine

Cysteine number	Peptide	Origin	Reference
2	Dodecapeptide	Ruminants	1
	Thanatin	Insects	2
	Bombinin	Amphibian	3
4	Tachyplesin	Tachypleus tridentatus	4
	Androctonin	Scorpion	5
	Protegrin	Pig	6
6	α -defensin	Leucocytes of mammalian	7
	β -defensin	Epithelial cells of mammalian	8
8	Hepcidin	Human liver	9

1. Romeo, D. et al., *J. Biol. Chem.*, 1988, 263, 9573-9575.

2. Fehlbauer, P. et al., *Proc, Natl, Acad, Sci.*,
5 1996, 93, 1221-1225.

3. Goraya, J. et al., *Eur. J. Biochem.*, 2000, 267, 894-900.

4. Iwanaga, S. et al., *J. Biochem.*, 1998, 123, 1-15.

10 5. Hetru, C. et al., *Biochem. J.*, 2000, 345, 653-664.

6. Ganz, T. et al., *Drugs*, 2000, 9, 1731-1742.

7. Lehrer, R.I. et al., *Annu. Rev. Immunol.*,
1993, 11, 105-128.

15 8. O'Neil, D.A. et al., *J. Immunol.*, 1999, 163, 6718-6724.

9. Krause, A. et al., *FEBS Lett.*, 2000, 480, 147-150.

Working mechanism and specificity of antimicrobial peptides depend on the way to work mutually with bacterial cell membranes. Generally, peptides are accepted through self-promoted uptake pathway by working with LPS (lipopolysaccharide) on the surface of Gram-negative bacteria. The first step of the accepting process is that the peptides are adhered to divalent cation-binding sites of LPS on cell surface, and the second step is that the peptides are inserted in cell membrane to form a channel.

In the first step, peptides can bind to LPS with 3 times as high affinity as divalent cations like Mn^{++} or Mg^{++} , so that they can be substituted for the divalent cations, causing a break down of a general property of cell membrane, especially of outer membrane. Such affected bacterial cell membrane makes a gap temporarily, through which hydrophobic substances, low-molecular proteins or antibiotics can pass and especially peptides are inserted effectively (Piers, K. L. et al., *Antimicrob. Agents Chemother.*, 1994, 38, 2311-2316).

In the second step, peptides are inserted in cell membrane to form a channel, during which magnetism of

cation peptides works with anions of bacterial membrane, so that hydrophobic region faces membrane and hydrophilic region faces inner side to form a channel (Hancock, R. E. et al., *Adv. Microbial Physiol.*, 1995, 37, 135-175). The channel is formed well when potential difference is big, the amount of anion lipids is great and the quantity of cholesterol is small. A well-formed channel causes a break down of membrane structure, resulting in the death of bacteria (Falla, T. et al., *J. Biol. Chem.*, 1996, 271, 19298-19303). On the contrary, eukaryotic cells containing a huge amount of cholesterol but a small quantity of anion lipid do not provide a good condition for the working of peptides. Thus, the peptides show a highly selective activity against bacteria. Based on the above reasons, antimicrobial peptides are noticed as novel antibiotics with less cytotoxicity. Besides, the advantages of antimicrobial peptides, as novel antibiotics, are as follows.

1. Preventing the appearance of resistant bacteria by destroying bacterial membrane physically.
2. Working faster than the life cycle of bacteria.
3. Working effectively on resistant bacteria having resistance against conventional antibiotics.
4. Having wide antimicrobial spectrum.
5. Having an anti-endotoxicity effect owing to the

binding capacity to LPS, etc.

6. Being able to be mass-produced using genetic engineering techniques and developed as a novel medicine with a less production cost.

5

From the viewpoint of animal systematic taxonomy, a tunicate belonging to deuterostomia is a kind of invertebrates classified into protochordata with such characteristics as having notochord and dorsal tubular nerve cord during tadpole larva period. Thus, a tunicate can be classified in pre-vertebrata with respect to systematic evolutionistics. Owing to such taxonomical position, a tunicate has been regarded as a model animal to prove evolutionary origin of animal immune system. Especially, the body cavity (hemocoel) of a tunicate was observed to have lots of phagocytes having similar forms and functions to granulocytes and macrophages found in circulatory system of vertebrata (Bone, Q., *The Origin of Chordates*, 1979, 2nd edn). Studies to detect out antimicrobial peptides from body fluid cells of a tunicate have been undergoing and clavanin (Lee, I. H. et al., *FEBS Lett.*, 1997, 400, 158-162 ; Lee, I. H. et al., *Infection and Immunity*, 1997, 65, 2898-2903 ; Zhao, C. et al., *FEBS Lett.*, 1997, 410, 490-492) and styelin (Lee, I. H. et al., *Comp. Biochem. Physiol. B Biochem. Mol. Biol.*, 1997, 118,

515-521; Zhao, C. et al., *FEBS Lett.*, 1997, 412, 144-148) separated from body fluid cells of *Styela clava* are the representative antimicrobial peptides found out so far.

5

Two kinds of tunicates inhabit in the country. One is *Halocynthia roretzi* inhabiting mainly in southwest seashores or raised artificially and the other is *Halocynthia aurantium*, also called "silky sea squirt", inhabiting only in Sokcho (Kangwon-Do, Korea) area of the east coast. The former has been studied in Japan many years and disclosed to have an antimicrobial substance in the shape of transformed peptide (tetrapeptide) like halocyamine (Azumi, K. et al., *Experientia*, 1990, 46, 1066-1068; K. Azumi et al., *Biochemistry*, 1990, 29, 159-165). But there is no report yet that an antimicrobial peptide is separated from the latter, *Halocynthia aurantium*.

20 Thus, the present inventors investigated if there is any antimicrobial peptide in body fluid cells of *Halocynthia aurantium*. As a result, the present inventors separated an antimicrobial peptide named as dicinthaurin (Lee, I. H. et al., *Biochem. Biophys. Acta*, 2001, in press), and further, separated another antimicrobial peptide recently. The present inventors

have accomplished this invention by analyzing the structure of the newly separated antimicrobial peptide and confirming the excellent antimicrobial activity thereof.

5

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

It is an object of the present invention to provide an antimicrobial peptide isolated from *Halocynthia aurantium* and an antimicrobial agent comprising the same as an active ingredient.

10

To achieve the above object, the present invention provides an antimicrobial peptide isolated from the body fluid of *Halocynthia aurantium* and an antimicrobial agent comprising the same as an active ingredient.

15

Hereinafter, the present invention is described in detail.

The present invention provides an antimicrobial peptide isolated from the body fluid of *Halocynthia aurantium*.

20

The antimicrobial peptide of the present invention is isolated from tunicate, wherein the tunicate is preferred to be *Halocynthia aurantium* called "silky sea squirt". However, it is a common


25

knowledge for the people in this field that the antimicrobial peptide of the present invention is not limited thereto and can be isolated from other organisms or synthesized artificially.

5

The present invention provides a peptide represented by <Chemical Formula 1> having 18 amino acids represented by each figures.

10 <Chemical Formula 1>



In the above <Chemical Formula 1>,

W represents tryptophane or its derivatives;

15 X represents more than one amino acid residue selected from a group consisting of tyrosine, valine, isoleucine, methionine, phenylalanine and tryptophane, and the derivatives thereof;

20 B represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine, and the derivatives thereof;

B' represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine or from a group consisting of asparagine

and glutamine, and the derivatives thereof; and

U represents more than one amino acid residue selected from a group consisting of glycine, serine, alanine and threonine, and the derivatives thereof.


5

As for the peptide of the present invention represented by the above <Chemical Formula 1>, it is preferable to select tryptophane for W, select one from a group consisting of leucine, isoleucine and valine for X, one from a group consisting of asparagine, glutamine, histidine, lysine and arginine for B, one from a group consisting of alanine, serine, and glycine for U, and select cysteine for C.

15 For building the peptide of the present invention represented by the above <Chemical Formula 1>, it is more preferable to select tryptophane for W₁, leucine for X₂, asparagine for B'₃, alanine for U₄, leucine for X₅, leucine for X₆, histidine for B₇, histidine for B₈,
20 glycine for U₉, leucine for X₁₀, asparagine for B'₁₁, cysteine for C₁₂, alanine for U₁₃, lysine for B₁₄, glycine for U₁₅, valine for X₁₆, leucine for X₁₇ and alanine for U₁₈. Thus, it is most preferable for the peptide of the present invention to have amino acid
25 sequence represented by SEQ. ID. No 1.

The present invention also provides a peptide having 15 amino acids represented by <Chemical Formula 2> in which three amino acids ($W_1X_2B'_3$) at N-terminal of the peptide represented by the above <Chemical Formula 1> are lost.

<Chemical Formula 2>



In the above Formula,

10 X represents more than one amino acid residue selected from a group consisting of tyrosine, valine, isoleucine, leucine, methionine, phenylalanine and tryptophane, and the derivatives thereof;

15 B represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine, and the derivatives thereof;

20 B' represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine or from a group consisting of asparagine and glutamine, and the derivatives thereof; and

U represents more than one amino acid residue selected from a group consisting of glycine, serine, alanine and threonine, and the derivatives thereof.


As for the peptide of the present invention represented by the above <Chemical Formula 2>, it is preferable to select one from a group consisting of leucine, isoleucine and valine for X, one from a group
5 consisting of asparagine, glutamine, histidine, lysine and arginine for B, one from a group consisting of alanine, serine, and glycine for U, and select cysteine for C.

10 For building the peptide of the present invention represented by the above <Chemical Formula 2>, it is more preferable to select alanine for U₄, leucine for X₅, leucine for X₆, histidine for B₇, histidine for B₈, glycine for U₉, leucine for X₁₀, asparagine for B'₁₁,
15 cysteine for C₁₂, alanine for U₁₃, lysine for B₁₄, glycine for U₁₅, valine for X₁₆, leucine for X₁₇ and alanine for U₁₈. Thus, it is most preferable for the peptide of the present invention to have amino acid sequence represented by SEQ. ID. No 2.

20

The present invention further provides a peptide in dimer form represented by <Chemical Formula 3> wherein the cysteine residues of two peptides, each represented by <Chemical Formula 1>, are combined with
25 each other by disulfide bond.


<Chemical Formula 3>



The above amino acids represented by each figures are the same as represented by <Chemical Formula 1> and
 5 the peptide is most preferably formed by combining two amino acids of peptides represented by SEQ. ID. No 1, the 12th amino acid each, together by disulfide bond.

The present invention also provides a peptide in
 10 dimer form represented by <Chemical Formula 4> wherein the cysteine residues of two peptides, each represented by <Chemical Formula 2>, are combined with each other by disulfide bond.

15 <Chemical Formula 4>




The above amino acids represented by each figures are the same as represented by <Chemical Formula 2> and
 20 the peptide is most preferably formed by combining two

amino acids of peptides represented by SEQ. ID. No 2,
the 9th amino acid each, together by disulfide bond.

The present invention also provides a peptide in
5 dimer form represented by <Chemical Formula 5> wherein
the cysteine residue of the peptide represented by
<Chemical Formula 1> is combined with that of the
peptide represented by <Chemical Formula 2> by
disulfide bond.

10

<Chemical Formula 5>



The above amino acids represented by each figures
are the same as represented in <Chemical Formula 1> and
15 <Chemical Formula 2>. For the peptide above, it is
most preferable to combine the 12th amino acid of the
peptide represented by SEQ. ID. No 1 and the 9th amino
acid of the peptide represented by SEQ. ID. No 2 by
disulfide bond.

20

In the preferred embodiment of the present
invention, the present inventors separated a peptide
represented as <Chemical Formula 5> from body fluid of

Halocynthia aurantium and confirmed that the peptide had antimicrobial activity. We, the present inventors named the peptide "halocidin". By detecting out the structure of halocidin, the present inventors confirmed that halocidin consisted of peptides represented as <Chemical Formula 1> and <Chemical Formula 2> in which cysteine residues were combined each other by disulfide bond (see FIG. 5). Named a peptide represented as <Chemical Formula 1> "18Hc" and a peptide represented as <Chemical Formula 2> "15Hc". In order to analyze the characteristics of halocidin, the present inventors prepared peptides in dimer form each represented as <Chemical Formula 3> and <Chemical Formula 4> using peptides represented as <Chemical Formula 1> and <Chemical Formula 2>, and then named them "di-18Hc" and "di-15Hc".

The inventors also named a peptide wherein a C-terminal amino acid was eliminated from 18Hc "(18-1)Hc" and a peptide wherein two C-terminal amino acids were eliminated "(18-2)Hc". In the same manner, Peptides wherein 3 to 6 C-terminal amino acids were removed were named "(18-3)Hc", "(18-4)Hc", "(18-5)Hc" and "(18-6)Hc" respectively. A peptide wherein all histidine residues were substituted with lysine was named "Hck". When lysine was added to N-terminal of a peptide, the letter "K" was added in the first place of the name of the

peptide and the added number of lysine was marked as (+) next to the number. For example, as one lysine was added to N-terminal of 18Hc, it was named "K(18+1)Hc".

The mass of peptides represented as <Chemical Formula 1 to 5> was measured, resulting in 1,929 Da, 1,516 Da, 3,861 Da, 3,031 Da and 3,445 Da, respectively (see Table 3). Especially, pI value of halocidin, a peptide represented as <Chemical Formula 5>, was 8.965 and halocidin was a peptide in hetero-dimer form having helical wheel structure (see FIG. 8).

In order to confirm if the peptides of the present invention represented as <Chemical Formula 1 to 5> have antimicrobial activity, performed radical diffusion analysis (see FIG. 9), colony counting analysis (see FIG. 10), hemolysis analysis (see FIG. 11), radical diffusion analysis on Gram negative strain (see FIG. 12, FIG. 13 and FIG. 14) and radical diffusion analysis on Gram positive strain (see FIG. 15, FIG. 16 and FIG. 17). As a result, it was disclosed that those peptides represented as <Chemical Formula 1 to 5> had great antimicrobial activity. Precisely, peptides in dimer forms represented as <Chemical Formula 2, 4 and 5> had greater antimicrobial activity and a peptide represented as <Chemical Formula 2> showed the greatest antimicrobial activity, above all.

In order to confirm if the peptides of the present invention still keep antimicrobial activity under strict conditions *in vivo*, measured antimicrobial activity of the peptides under the condition of pH 5.5 that was the same acidic condition as the environment in epithelial cells, urethra, vagina, etc, and NaCl 200 mM that was higher than basic condition of intra-blood (NaCl 150 mM). As a result, it was confirmed that a peptide represented as <Chemical Formula 5> showed antimicrobial activity under the condition of pH 5.5 - pH 7.4 (see Table 4) and NaCl 100 mM - NaCl 200 mM as well (see Table 5).

Based on the above results, the peptides of the present invention represented as <Chemical Formula 1 to 5> were proved to have excellent antimicrobial activity, comparing to the conventional antibiotics. Particularly, the peptides were confirmed to have excellent antimicrobial activity under strong acidic and basic environments, and have strong antimicrobial activity against resistant bacteria.

The present invention further provides an antimicrobial agent containing the above-mentioned peptide as an active ingredient.

As explained hereinbefore, the peptide of the

present invention has an excellent antimicrobial activity under strong acidic and basic environments. So, it can be effectively used as an antimicrobial agent.

5 Thus, the peptide of the present invention can be included as an active ingredient for preparing an antimicrobial agent. The antimicrobial agent of the present invention can be administered orally or parenterally and be used in general form of
10 pharmaceutical formulation.

 The antimicrobial agent of the present invention can be prepared for oral or parenterally administration by mixing with generally-used fillers, extenders, binders, wetting agents, disintegrating agents,
15 diluents such as surfactant, or excipients. Solid formulations for oral administration are tablets, pill, dusting powders and capsules. These solid formulations are prepared by mixing one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose,
20 gelatin, etc with one or more halocidin. Except for the simple excipients, lubricants, for example magnesium stearate, talc, etc, can be used. Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the abovementioned
25 formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives

in addition to generally used simple diluents such as water and liquid paraffin. Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, emulsions, and
5 suppositories. Water insoluble excipients and suspensions can contain, in addition to the active compound or compounds, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc. Suppositories can contain, in
10 addition to the active compound or compounds, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerinated gelatin, etc.

In general, it has proved advantageous both in human and in veterinary medicine to administer the
15 active compound or compounds according to the present invention in total amounts of about 0.5 mg/kg to about 1 mg/kg, preferably 0.1-0.5 mg/kg of body weight, one to two times every 24 hours, if appropriate, in the form of several individual doses, to achieve the desired
20 results.

The antimicrobial agent of the present invention can be used widely as an antibacterial agent or an antiviral agent to control virus, Gram positive bacteria, Gram negative bacteria, fungi, yeast and
25 protozoa harming plants, animals and human. The antimicrobial agent of the present invention can be

used either independently or together with other antibiotics such as erythromycin, tetracycline, azithromycin, vancomycin, cephalosporins, etc. Further, the antimicrobial agent of the present invention can also be used as food additives, cosmetics, ointments, injections, etc.

BRIEF DESCRIPTION OF THE DRAWINGS

The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:

FIG. 1 is an AU-PAGE photograph showing the purification process of halocidin from *Halocynthia aurantium*;

Lane 1: Acidic extracts of body fluid cells of *Halocynthia aurantium*,

Lane 2: 51st-81st fractions passed through Sepadex G-50 column,

Lane 3: 35th-45th fractions passed through Prep. AU-PAGE, and

Lane 4: Halocidin purified by RP-HPLC

FIG. 2 is a graph showing the result of C18 RP-HPLC with purified halocidin;

FIG. 3 is a photograph showing the result of SDS-PAGE with purified halocidin;

Lane M: Standard molecular weight marker,

5 Lane 1: Natural halocidin, and

Lane 2: Halocidin cut by dithiothreitol

FIG. 4 is a graph showing the result of MALDI mass analysis with purified halocidin;

10

FIG. 5 is a diagram showing the structure and amino acid sequence of the two constituents of halocidin;

15 FIG. 6 is a set of graphs showing the result of RP-HPLC with a natural halocidin and a synthetic halocidin;

A: 15Hc and 18Hc,

B: di-15Hc, di-18Hc and halocidin,

20 C: Natural halocidin

FIG. 7 is a set of graphs showing the CD spectra of 18Hc suspended in phosphate buffer (pH 7.4) (pink line), 20 mM SDS phosphate buffer (pH 7.4) (black line) and 10 mM phosphate buffer containing 50% (v/v) trifluoroethanol (pH 7.4) (red line);

25

A: 18Hc,

B: di-18Hc

FIG. 8 is a set of a photograph and a graph showing the helical diagram (A) and pI (B) of halocidin (18Hc);

FIG. 9 is a set of photographs and graphs showing the result of radical diffusion analysis of a peptide affecting MRSA (A and C) and MDRPA (B and D);

10 a: 15Hc, b: di-15Hc,
 c: 18Hc, d: di-18Hc,
 e: Halocidin, f: Magainin 1,
 g: Bufforin 2

15 FIG. 10 is a set of graphs showing the antimicrobial activity of a peptide measured by colony counting analysis;

FIG. 11 is a graph showing the result of hemolytic assay with a peptide;

FIG. 12 is a set of graphs comparing antimicrobial activities of 15Hc, 18Hc, halocidin, bufforin 2 and magainin 1 to Gram-negative bacteria;

25 A: *Pseudomonas aeruginosa*,
 B: *Salmonella cholerasuis*,

C: *Salmonella paratyphi* A,

D: *E.coli* K112 and

E: *E.coli* DH5a

5 FIG. 13 is a set of graphs comparing
antimicrobial activities of (18-1)Hc, di-(18-2)Hc, 18Hc
and di-18Hc to Gram-negative bacteria;

A: *Pseudomonas aeruginosa*,

B: *Salmonella cholerasuis*,

10 C: *Salmonella paratyphi* A,

D: *E.coli* K112 and

E: *E.coli* DH5a

FIG. 14 is a set of graphs comparing
15 antimicrobial activities of (18-2)Hc, di-(18-2)Hc,
(18)Hck and di-(18)Hck to Gram-negative bacteria;

A: *Pseudomonas aeruginosa*,

B: *Salmonella cholerasuis*,

C: *Salmonella paratyphi* A,

20 D: *E.coli* K112 and

E: *E.coli* DH5a

FIG. 15 is a set of graphs comparing
antimicrobial activities of 15Hc, 18Hc, halocidin,
25 bufforin 2 and magainin 1 to Gram-positive bacteria;

A: *Staphylococcus aureus*,

B: *Micrococcus luteus*,
C: *Enterococcus faecalis*,
D: *Bacillus subtilis* and
E: MRSA

5

FIG. 16 is a set of graphs comparing antimicrobial activities of (18-1)Hc, di-(18-1)Hc, 18Hc and di-18Hc to Gram-positive bacteria;

A: *Staphylococcus aureus*,
B: *Micrococcus luteus*,
C: *Enterococcus faecalis*,
D: *Bacillus subtilis* and
E: MRSA

10

15

FIG. 17 is a set of graphs comparing antimicrobial activities of (18-2)Hc, di-(18-2)Hc, (18)Hck and di-(18)Hck to Gram-positive bacteria;

A: *Staphylococcus aureus*,
B: *Micrococcus luteus*,
C: *Enterococcus faecalis*,
D: *Bacillus subtilis* and
E: MRSA

20

EXAMPLES

25

Practical and presently preferred embodiments of

the present invention are illustrative as shown in the following Examples.

However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may
5 make modifications and improvements within the spirit and scope of the present invention.

Example 1: Isolation of an antimicrobial peptide from

Halocynthia aurantium

10 <1-1> Isolation of acid extract from *Halocynthia aurantium*

Bought *Halocynthia aurantium*, called silky sea squirt, at a fish market in Sockcho, Kangwon-Do, Korea, washed the outer skin alive with 70% ethanol, and dried
15 thereof. Cut the exhalent opening of the dried tunicates crossways and put thereof into a 50 ml tube containing 150 mg of EDTA to collect hemolymph. Removed impurities from the obtained hemolymph using 74 μ m pore sized mesh filter (Netwell, Corning Costar, Cambridge,
20 MA, USA), after which centrifuged thereof at 4°C with 300 g for 30 minutes. After centrifugation, suspended precipitated body fluid cells, hemocytes, in 30 ml of 0.34 M sucrose solution and centrifuged again at 4°C with 300 g for 30 minutes. On completing

centrifugation, isolated newly formed cell layer and suspended thereof in 10 ml of cooled 5% acetic acid solution. After sonication with the above suspension 5 times 15 seconds each, added 40 ml of 5% acetic acid solution thereto. Mixed the solution extracted by acetic acid at 4°C for overnight, followed by centrifuging at 4°C with 20,000 g for 30 minutes. Used the obtained supernatants from centrifugation as a test material for purifying antimicrobial peptides.

10 Quantified the protein of acid extracts from *Halocynthia aurantium* using bicinchoninic acid (Sigma) and obtained eluting fractions by loading the supernatants containing at least 50 mg of protein to Sephadex G-50 gel filtering column (Sigma) equilibrated with 5% acetic acid solution.

<1-2> Antimicrobial activity of acid extracts of *Halocynthia aurantium*

In order to measure the antimicrobial activity of acid extracts of *Halocynthia aurantium* obtained in the above Example <1-1>, the present inventors performed ultrasensitive radial diffusion assay. Particularly, analyzed 150 fractions eluted in the above Example <1-1> 5 times each. Took 100 μ l from 2 ml of each fraction and concentrated thereof with a vacuum centrifugation (Centra Evaporator, Bioneer, Korea), which was

suspended in 5 μ l of 0.01% acetic acid solution. Meanwhile, prepared agarose plate including wells 3 mm in diameter by adding methicillin resistance *Staphylococcus aureus* (referred as "MRSA" hereinafter, Seoul Women's University, Korea CCARM3001) of mid-logarithmic phase to gel comprising sterilized citrate phosphate buffer (9 mM sodium phosphate, 1 mM sodium citrate, pH 7.4), 1%(w/v) type 1 agarose (low electroendosmosis agarose) (A 6013, Sigma) and 3% tryptic soy broth (TSB, Difco, Detroit, MI, USA). Loaded the above fractions onto the wells of agarose plate containing the above bacteria. Reacted thereof for 3 hours to make the peptides spread into the agarose gel. Added 10 ml of overnutrition medium comprising 6% TSB and 1% agarose gel thereto. Cultured the above plate for overnight until the colonies of the above bacteria were formed. Confirmed the antimicrobial activity of the loaded peptide by measuring the diameter of clearing zone formed around the loaded peptide fraction.

As a result, the clearing zones formed around #51-#81 peptide fractions were the biggest, suggesting that the fractions had high antimicrobial activity.

<1-3> Purification of peptide in fractions having

antimicrobial activity

In order to purify peptide fractions having antimicrobial activity more clearly, centrifuged #51-
#81 fractions that were confirmed to have antimicrobial
5 activity in the pre-stage, concentrated and loaded
thereof on preparative acid urea polyacrylamide gel
electrophoresis (referred "Prep AU-PAGE" hereinafter).
Adjusted the current speed of Prep AU-PAGE to 60 ml
/hour and divided by 2 ml for a fraction.

10 Put Prep AU-PAGE fractions in 2 ml tubes and
concentrated with a rotary concentrator. Performed
electrophoresis with each fraction at intervals of 10
numbers in two AU-PAGE gels. Stained one gel with
Coomasie blue to confirm bands and investigated the
15 antimicrobial activity of protein bands of the other
gel with gel overlay assay using MRSA. For the gel
overlay assay, put the electrophoresed gel on 10 ml of
underlay agar containing MRSA and let it to be reacted
at 37°C for 3 hours in order for the peptides to
20 diffuse into agarose gel, after which poured 10 ml of
over-nutrition medium (6% TSB and 1% agarose gel).

As a result, proteins contained in #35-#45
fractions were confirmed to have antimicrobial activity
(FIG. 1).

25

In order to purify #35-#45 fractions that were

confirmed to have antimicrobial activity finally, loaded them to C18 reverse phase high performance liquid chromatography (referred as "RP-HPLC" hereinafter) column (Vydac 218TP54: The Separation Group, Hesperia, CA). For the first 10 minutes after loading those samples, washed the column by spilling 5% acetonitrile containing 0.1% trifluoroacetic acid (TFA) at the speed of 0.5 ml/minute. Thereafter, increased the concentration of acetonitrile by 1%/minute for 60 minutes. During the process, collected peak fraction of each concentration of acetonitrile. Concentrated 10% of each collected fraction with a vacuum rotary concentrator, followed by confirming antimicrobial activity with radial diffusion analysis.

As a result, confirmed that a peptide isolated at 50.2 minute at which the concentration of acetonitrile reached 45.2% had antimicrobial activity and named it "halocidin" (FIG. 2).

Example 2: Analysis of characteristics of purified halocidin

<2-1> Mass analysis of halocidin

In order to clarify characteristics of halocidin, a novel peptide having antimicrobial activity, isolated

from *Halocynthia aurantium* in the above Example 1, the present inventors performed SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and AU-PAGE. Particularly, after freeze-drying halocidin, a peptide
5 having antimicrobial activity, isolated in the above Example 1, added 25 μ l of 8 M urea and 25 μ l of 0.4 M ammonium bicarbonate (pH 8.0) and melted. Added 45 mM dithiothreitol thereto and induced reaction at 50°C for 15 minutes. In order to produce a vinylpyridine
10 derivative of halocidin monomer, added 15 μ l of vinylpyridine to the above halocidin mixture and cooled thereof at room temperature, after which let the mixture to be reacted in the dark condition at least for 30 minutes. Extracted the final reactants with RP-
15 HPLC. Performed Tricine SDS-PAGE and AU-PAGE to confirm whether the product was correctly extracted, measured the molecular weight of the extracted halocidin with MALDI (matrix-associated laser desorption ionization) mass analyzer (Voyager-DE STR,
20 PerSeptive Biosystems, USA) and analyzed amino acid sequences with a Gas-phase Edman degradation method using Procise 419 (Applied Biosystems, USA).

As a result, it was confirmed that the mass of halocidin extracted by RP-HPLC and halocidin monomers
25 cut by dithiotreitol were 3.4 kDa and 1.5 and 1.8 kDa respectively (FIG. 3), and major peak of halocidin was

seen at the point of 3443.6836 m/z and minor peaks were seen at the points of 1515.7487 m/z and 1929.9151 m/z (FIG. 4). The structure of halocidin was also confirmed in which cysteine residues of a monomer consisting of 18 amino acids was combined with cysteine residues of another monomer consisting of 15 amino acids by disulfide bond (FIG. 5).

Conclusively, the present inventors found out that halocidin, a peptide having antimicrobial activity isolated from *Halocynthia aurantium*, has 3,443.7 Da molecular weight and is constructed by 15 monomer and 18 monomer in which cysteine residues were combined each other by disulfide bonds. Finally, the present inventors named 18 monomer and 15 monomer forming halocidin "18Hc" and "15Hc" respectively.

<2-2> Preparation of synthetic halocidin and comparing the mass of the synthetic halocidin with that of *Halocynthia aurantium* halocidin

After confirming the structure of halocidin formed by 15Hc and 18Hc, the present inventors prepared synthetic peptides in order to analyze and compare the characteristics thereof. Particularly, artificially synthesized halocidin monomers using an automatic solid-phase peptide synthesizer (Pioneer, Applied

Biosystems, USA) and purified with RP-HPLC. Mixed 1 mg /ml of each synthesized peptide for homodimer or heterodimer (halocidin) formed by 15 monomer and 18 monomer in 0.1 M ammonium bicarbonate solution and let
 5 the mixture in the air over 72 hours, resulted in the completion of synthetic peptides. Measured the mass of synthesized monomers, homodimers and heterodimers using a MALDI mass analyzer, by which confirmed if halocidin was correctly synthesized.

10 The sequences of synthesized peptide monomers are shown in Table 2.

<Table 2>

Peptide	Sequence	Sequence list
18Hc	WLNALLHHGLNCAKGVLA	SEQ. ID. No 1
(18-1)Hc	WLNALLHHGLNCAKGV	SEQ. ID. No 3
(18-2)Hc	WLNALLHHGLNCAKGV	SEQ. ID. No 4
(18-3)Hc	WLNALLHHGLNCAKG	SEQ. ID. No 2
(18-4)Hc	WLNALLHHGLNCAK	SEQ. ID. No 5
(18-5)Hc	WLNALLHHGLNCA	SEQ. ID. No 6
(18-6)Hc	WLNALLHHGLNC	SEQ. ID. No 7
(18)Hck	WLNALLKKGLNCAKGVLA	SEQ. ID. No 8
K(18+1)Hc	KWLNALLHHGLNCAKGVLA	SEQ. ID. No 9
K(18+1)Hck	KWLNALLKKGLNCAKGVLA	SEQ. ID. No 10

15 As a result, it was confirmed that the expected masses of *Halocynthia aurantium* halocidin and synthetic

halocidin and the masses after measuring with a MALDI mass analyzer were all the same (Table 3).

<Table 3>

	Peptide	Expected mass	MALDI measured mass
<i>Halocynthia aurantium</i> halocidin	15Hc	1515.9	1515.74
	18Hc	1929.4	1929.91
	Halocidin	3443.3	3443.68
Synthetic halocidin	15Hc	1515.9	1515.70
	18Hc	1929.4	1928.92
	di-15Hc	3029.8	3031.07
	di-18Hc	3856.8	3861.06
	Halocidin	3443.3	3445.04

5

<2-3> Comparison of elution peaks of *Halocynthia aurantium* halocidin and synthetic halocidin

The present inventors performed RP-HPLC to re-confirm eluting peaks of *Halocynthia aurantium* halocidin and synthetic halocidin that had same masses as seen in the above Example <2-2>. Particularly, loaded the solution containing *Halocynthia aurantium* halocidin extracted by acetonitrile to RP-HPLC column and spilled 5% acetonitrile into the column for 10 minutes (1 minute/ml). Measured the fractions eluted by the time. As a result, two monomers (15Hc and 18Hc) of *Halocynthia aurantium* were eluted at the 42nd minute

with 36.8% acetonitrile concentration and at the 52nd minute with 46.3% acetonitrile concentration respectively (FIG. 6A). Meanwhile, two homodimers, di-15Hc and di-18Hc, were eluted from the fractions with 39.2% acetonitrile concentration and with 51.7% acetonitrile concentration respectively. Heterodimers forming the structure of halocidin were eluted from the fractions with the same acetonitrile concentrations (FIG. 6C) as the case of eluting natural halocidin (FIG. 6B).

<2-4> Identification of the secondary structure of halocidin

In order to identify the secondary structure of halocidin, the present inventors investigated CD spectra of the halocidin. Particularly, suspended 18Hc and di-18Hc in phosphate buffer (pH 7.4), 20 mM SDS phosphate buffer (pH 7.4) and 50%(v/v) trifluorethanol 10 mM phosphate buffer (pH 7.4) at 25°C using 1 mm rectangular cell. Measured circular dichroism spectrum using CJ-715 CD/ORD sepectropolaimeter (JASCO.Co).

As a result, 18Hc and di-18Hc were confirmed to have α -helix structure having maximum value at the point of 193 nm and two minimum values at the points of 208 nm and 222 nm when being suspended in 20 mM SDS phosphate buffer and 50%(v/v) trifluorethanol 10 mM

phosphate buffer (FIG. 7).

<2-5> Measurement of helical wheel diagram and pI

In order to confirm the characteristics of
5 halocidin more accurately, the present inventors
measured helical wheel diagram and pI using ANTHEPROT
2000 V 5.2 software. As a result, confirmed the fact
that 18Hc has a helical wheel structure and
amphipathicity resulted from clustering of polar and
10 non-polar residues (FIG. 8A). Measured electric
charges of 18Hc by pH change, resulting in the
confirmation that pI of 18Hc is 8.965 (FIG. 8B).

Example 3: Analysis of antimicrobial activity of
15 halocidin

In order to analyze antimicrobial activity of a
novel antimicrobial peptide halocidin isolated from
Halocynthia aurantium, the present inventors performed
ultra-sensitive radical diffusion assay, colony
20 counting assay, hemolytic assay and antimicrobial
activity analysis against Gram-positive or Gram-
negative bacteria.

<3-1> Ultra-sensitive radical diffusion assay

The present inventors performed ultra-sensitive radical diffusion assay with synthetic peptides prepared in the above Example <2-2>. Particularly, measured antimicrobial activity of each 15Hc, di-15Hc, 5 18Hc, di-18Hc, halocidin, magainin 1 (Sigma)(control group) and buforin 2 (Sigma)(comparative group) against MRSA and multi drug resistance *Pseudomonas aeruginosa* (referred as "MDRPA" hereinafter)(Seoul Women's University CCARM2002) according to the concentration of 10 the peptides.

As a result, it was confirmed that buforin 2 that was known to have high antimicrobial activity to MRSA strain was proved to have antimicrobial activity by that the diameter of clear zone was enlarged as the 15 concentration increased. 18Hc, di-18Hc and halocidin were confirmed to have higher antimicrobial activity than buforin 2 as the concentration increased. Especially, di-18Hc showed the highest antimicrobial activity (FIG. 9A and FIG. 9C). Meanwhile, magainin 1 20 and buforin 2 were proved to have antimicrobial activity to MDRPA strain. And, 15Hc, di-15Hc, 18Hc, di-18Hc and halocidin were proved to have higher antimicrobial activity than comparative group (FIG. 9B and FIG. 9D).

25 Based on the above results, the present inventors confirmed that *Halocynthia aurantium* halocidin has high

antimicrobial activity, and especially, peptides in the form of homodimer constructed by 15-monomer and 18-monomer, which are constituents of halocidin, have higher antimicrobial activity rather than halocidin itself.

<3-2> Colony counting assay

In order to investigate antimicrobial activity of halocidin, the present inventors performed colony counting assay. Particularly, adjusted the final concentration of the peptide to 5 $\mu\text{g}/\text{ml}$ by mixing the peptide and MRSA strain or MDRPA strain of mid-log phase in sterilized 10 mM sodium phosphate buffer (pH 7.4) containing 0.3 mg/ml of TSB powder. Adjusted the final volume of the above mixture to 100 μl , and then let it be pre-reacted in a 37°C shaking water bath for 5 and 15 minutes each. Collected 20 μl of pre-reacted solution and loaded thereof onto 1.5% bacto-agar plate (Difco). Induced reaction for overnight and counted the number of formed colonies on the above plate, from which measured the antimicrobial activity. Used magainin 1 and buforin 2 for comparative group, and 0.01% acetic acid for control group.

As a result, comparative group and control group hardly showed antimicrobial activity to MRSA strain and MDRPA strain while 18Hc, di-18Hc and halocidin showed

high antimicrobial activity from 5 minutes after reaction began, which was continued until the 15 minutes after reaction. Especially, di-18Hc showed the highest antimicrobial activity and 18Hc and halocidin followed in order (FIG. 10). From the above results, the present inventors confirmed that 18Hc monomer or dimer, constituents of halocidin, has higher antimicrobial activity than halocidin itself.

10 <3-3> Hemolytic assay

In order to investigate antimicrobial activity of halocidin, the present inventors performed hemolytic assay. Particularly, mixed 20 μl of peptide diluted to 100, 50, 25, 12.5, 6.25, 3.125 $\mu\text{g/ml}$ and 180 μl of 2.5% (V/V) human erythrocytes in PBS. Used melittin (Sigma) and clavanin AK, a congener in which clavanin A residue was substituted, for comparative group, and 0.01% acetic acid for control group. After reacting the mixture at 37°C for 30 minutes, added 600 μl of PBS into each tube. Centrifuged the solution at 10,000 g for 3 minutes and separated supernatants. Measured OD at 540 nm and calculated the hemolytic activity (%) according to the below <Mathematical Formula 1>.

25 <Mathematical Formula 1>

Sample A₅₄₀ □ Control Group A₅₄₀

$$\text{Hemolytic Activity (\%)} = \frac{\text{Sample A}_{540} - \text{Control Group A}_{540}}{100\% \text{ Comparative Group A}_{540} - \text{Control Group A}_{540}} \times 100$$

5 As a result, the hemolytic activity of each peptide di-18Hc, 18Hc, 15Hc, di-15Hc and halocidin was proved to be 18%, 9%, 0% and 0% (FIG. 11). Therefore the hemolytic activity of di-18Hc was the highest.

10 <3-4> Comparing antimicrobial activity to Gram negative bacteria

 The present inventors confirmed the antimicrobial activity of halocidin to Gram-negative bacteria with radical diffusion assay. Particularly, investigated
15 antimicrobial activities of 15Hc, 18Hc and halocidin to Gram negative bacteria such as *Pseudomonas aeruginosa*, *Salmonella cholerasuis*, *Salmonella paratyphi A*, *E.coli* K112 and *E.coli* DH5a . At that time, used buforin 2 and magainin 1 for comparative group.

20 As a result, 15Hc and 18Hc hardly showed or had minimum antimicrobial activity even though the concentration of peptide increased. However, halocidin showed almost the same level of antimicrobial activity as magainin 1 and buforin 2, which were the comparative
25 group, or higher antimicrobial activity than comparative group according to the kinds of bacteria

(FIG. 12).

The present inventors performed radical diffusion assay again for (18-1)Hc, di-(18-1)Hc, 18Hc and di-18Hc with the same method as the above. As a result, di-
5 (18-1)Hc and di-18Hc, which were in dimer form, showed higher antimicrobial activity than (18-1)Hc and 18Hc, which were in monomer forms, though it varied upon the kinds of bacteria (FIG. 13).

The present inventors performed radical diffusion
10 assay for (18-2)Hc, di-(18-2)Hc, (18)Hck and di-(18)Hck with the same method as the above. As a result, di-(18-2)Hc and di-(18)Hck, which were in dimer forms, showed higher antimicrobial activity than (18-2)Hc and (18)Hck, which were in monomer forms (FIG. 14).

15

Based on the above results, the present inventors confirmed that halocidin had high antimicrobial activity to Gram-negative bacteria and showed the highest activity when monomers, subunits of halocidin,
20 were in dimer forms.

<3-5> Comparing antimicrobial activity to Gram positive bacteria

The present inventors investigated the
25 antimicrobial activity of halocidin to Gram-positive bacteria. Particularly, performed radical diffusion

assay with the same method as the above Example 1 to confirm the antimicrobial activity of each 15Hc, 18Hc, halocidin, buforin 2 and magainin 1 to Gram-positive bacteria such as *Staphylococcus aureus*, *Micrococcus*
5 *luteus*, *Enterococcus faecalis*, *Bacillus subtilis* and MRSA.

As a result, just halocidin showed high antimicrobial activity. 15Hc and 18Hc were proved to have low antimicrobial activity (FIG. 15).

10 The present inventors performed radical diffusion assay again for (18-1)Hc, di-(18-1)Hc, 18Hc and di-18Hc with the same method as the above. As a result, di-(18-1)Hc and di-18Hc, which were in dimer forms, showed higher antimicrobial activity than (18-1)Hc and 18Hc,
15 which were in monomer forms, though it varied upon the kinds of bacteria (FIG. 16).

The present inventors performed radical diffusion assay for (18-2)Hc, di-(18-2)Hc, (18)Hck and di-(18)Hck with the same method as the above. As a result, di-
20 (18-2)Hc and di-(18)Hck, which were in dimer forms, showed higher antimicrobial activity than (18-2)Hc and (18)Hck, which were in monomer forms (FIG. 17).

Based on the above results, the present inventors
25 confirmed that halocidin had high antimicrobial activity to Gram-positive bacteria and showed the

highest activity when monomers, subunits of halocidin, were in dimer forms.

<3-6> Antimicrobial activity according to pH

5 In order to confirm if halocidin having high antimicrobial activity to bacteria still keeps the activity under the low pH condition *in vivo*, the present inventors investigated the change of antimicrobial activity according to pH by radical
10 diffusion assay. Particularly, adjusted the pH of media to 7.4, 6.5 and 5.5 respectively by adding HCl, which was checked with a pH meter, and performed radical diffusion assay with the same method as the above Example 1 to investigate the antimicrobial
15 activity to MRSA and *Enterococcus faecalis*.

 As a result, it was confirmed that di-18Hc, di-(18-1)Hc and di-k(18+1)Hc kept the same antimicrobial activity even under low pH condition, pH 5.5, which was similar condition to the environment of epithelial
20 tissue, urethra, intravagina, etc, as that under pH 7.4 (Table 4).

25 <Table 4>

Peptide		MRSA	<i>Enterococcus faecalis</i>
pH=7.4	Halocidin	>64	>64
	K(18+1)Hc	16-32	8-16
	di-(18-1)Hc	8-16	8-16
	di-18Hc	8-16	2-4
	di-K(18+1)Hc	2-4	2-4
	P18	8-16	32-64
	Magainin 1	>64	>64
	Buforin 2	>64	>64
	Secrofin A	>64	>64
pH=6.5	Halocidin	>64	>64
	K(18+1)Hc	16-32	16-32
	di-(18-1)Hc	2-4	4-8
	di-18Hc	2-4	4-8
	di-K(18+1)Hc	2-4	2-4
	P18	32-64	>64
	Magainin 1	>64	>64
	Buforin 2	>64	>64
	Secrofin A	>64	>64
pH=5.5	Halocidin	>64	>64
	K(18+1)Hc	32-64	16-32
	di-(18-1)Hc	8-16	2-4
	di-18Hc	4-8	2-4
	di-K(18+1)Hc	2-4	2-4
	P18	>64	>64
	Magainin 1	>64	>64
	Buforin 2	>64	>64
	Secrofin A	>64	>64

<3-7> Antimicrobial activity according to base

The present inventors confirmed if halocidin still had antimicrobial activity under the strong basic condition *in vivo*. Particularly, changed the basic condition of media by adding 100 mM NaCl, 150 mM NaCl and 200 mM NaCl respectively, and investigated the antimicrobial activity to MRSA and *Enterococcus faecalis* by radical diffusion assay.

As a result, it was confirmed that di-18Hc, di-(18-1)Hc and di-k(18+1)Hc kept the same antimicrobial activity even under strong basic condition (200 mM) as that under non-basic condition (Table 5).

15 <Table 5>

Peptide		MRSA	<i>Enterococcus faecalis</i>
NaCl 100 mM	Halocidin	>64	>64
	K(18+1)Hc	16-32	16-32
	di-(18-1)Hc	4-8	8-16
	di-18Hc	8-16	2-4
	di-K(18+1)Hc	4-8	2-4
	P18	>64	>64
	Magainin 1	>64	>64
	Buforin 2	>64	>64
	Secrofin A	>64	>64


NaCl 150 mM	Halocidin	>64	>64
	K(18+1)Hc	16-32	16-32
	di-(18-1)Hc	8-16	8-16
	di-18Hc	8-16	2-4
	di-K(18+1)Hc	4-8	2-4
	P18	>64	>64
	Magainin 1	>64	>64
	Buforin 2	>64	>64
	Secrofin A	>64	>64
NaCl 200 mM	Halocidin	>64	>64
	K(18+1)Hc	32-64	16-32
	di-(18-1)Hc	8-16	8-16
	di-18Hc	16-32	2-4
	di-K(18+1)Hc	4-8	2-4
	P18	>64	>64
	Magainin 1	>64	>64
	Buforin 2	>64	>64
	Secrofin A	>64	>64

Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.

What is claimed is

1. A peptide separated from tunicate and comprising amino acid sequence represented by the below
5 <Chemical Formula 1> in which each amino acid is represented by each figure;

<Chemical Formula 1>



10 In the above Formula,

W represents tryptophane or its derivatives;

X represents more than one amino acid residue selected from a group consisting of tyrosine, valine, isoleucine, methionine, phenylalanine and tryptophane,
15 and the derivatives thereof;

B represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine, and the derivatives thereof;

B' represents more than one amino acid residue
20 selected from a group consisting of arginine, lysine and histidine or from a group consisting of asparagine and glutamine, and the derivatives thereof; and

U represents more than one amino acid residue

selected from a group consisting of glycine, serine, alanine and threonine, and the derivatives thereof.

2. The peptide as set forth in claim 1, wherein the
5 tunicate is *Halocynthia aurantium*.

3. The peptide as set forth in claim 1, wherein the W
is tryptophane, the X is one selected from a group
consisting of leucine, isoleucine and valine, the B
10 is one selected from a group consisting of
asparagine, glutamine, histidine, lysine and
arginine, the U is one selected from a group
consisting of alanine, serine, and glycine, and the
C is cysteine.

15


4. The peptide as set forth in claim 1, wherein the
peptide is consisted of amino acid sequence
represented by SEQ. ID. No 1 in which W₁ is
tryptophane, X₂ is leucine, B'₃ is asparagine, U₄ is
20 alanine, X₅ is leucine, X₆ is leucine, B₇ is
histidine, B₈ is histidine, U₉ is glycine, X₁₀ is
leucine, B'₁₁ is asparagine, C₁₂ is cysteine, U₁₃ is
alanine, B₁₄ is lysine, U₁₅ is glycine, X₁₆ is valine,
X₁₇ is leucine and U₁₈ is alanine.

25

5. A peptide comprising amino acid sequence represented

by the below <Chemical Formula 2> in which three amino acids ($W_1X_2B'_3$) of the peptide represented by the above <Chemical Formula 1> are lost;

5 <Chemical Formula 2>



In the above Formula,

U represents more than one amino acid residue selected from a group consisting of glycine, serine, alanine and threonine, and the derivatives thereof;

X represents more than one amino acid residue selected from a group consisting of tyrosine, valine, isoleucine, leucine, methionine, phenylalanine and tryptophane, and the derivatives thereof;

15 B represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine, and the derivatives thereof; and

B' represents more than one amino acid residue selected from a group consisting of arginine, lysine and histidine or from a group consisting of asparagine and glutamine, and the derivatives thereof.

6. The peptide as set forth in claim 5, wherein the X is selected from a group consisting of leucine,

isoleucine and valine, the B is selected from a group consisting of asparagine, glutamine, histidine, lysine and arginine, the U is selected from a group consisting of alanine, serine, and glycine, and the C is cysteine.

5

10


7. The peptide as set forth in claim 5, wherein the peptide is consisted of amino acid sequence represented by SEQ. ID. No 2 in which U₄ is alanine, X₅ is leucine, X₆ is leucine, B₇ is histidine, B₈ is histidine, U₉ is glycine, X₁₀ is leucine, B'₁₁ is asparagines, C₁₂ is cysteine, U₁₃ is alanine, B₁₄ is lysine, U₁₅ is glycine, X₁₆ is valine, X₁₇ is leucine and U₁₈ is alanine.

15

20

8. A peptide represented by the below <Chemical Formula 3> wherein the peptide represented by <Chemical Formula 1> of claim 1 is combined with the other peptide represented by <Chemical Formula 2> of claim 5 at cysteine site by disulfide bond;


<Chemical Formula 3>



9. A peptide represented by the below <Chemical Formula 4> wherein the two peptides represented by <Chemical Formula 1> of claim 1 are combined with each other at cysteine site by disulfide bond;

5


<Chemical Formula 4>



10. A peptide represented by the below <Chemical Formula 5> wherein the two peptides represented by <Chemical Formula 2> of claim 5 are combined with each other at cysteine site by disulfide bond;

10

<Chemical Formula 5>




11. An antimicrobial agent comprising one or more peptides selected from a group consisting of compounds represented by <Chemical Formula 1 - 5> as an active ingredient.

15

1/16


FIGURES

FIG. 1




2/16

FIG. 2



3/16

FIG. 3



4/16

FIG. 4






FIG. 5




5/16

FIG. 6





6/16

FIG. 7




7/16

FIG. 8




8/16

FIG. 9




9/16

FIG. 10




10/16

FIG. 11




11/16

FIG. 12



12/16

FIG. 13




right axis: Peptide concentration(ug/ml)

left axis: antimicrobial activity(%)

13/16

FIG. 14




right axis: Peptide concentration(ug/ml)

left axis: antimicrobial activity(%)


14/16

FIG. 15




15/16

FIG. 16



16/16

FIG. 17



SEQUENCE LISTING

<110> LEE, In Hee
SON, Seok Min

<120> Antimicrobial peptide isolated from *Halocynthia aurantium*

<130> 2fpo-11-41

<160> 10

<170> KopatentIn 1.71

<210> 1

<211> 18

<212> PRT

<213> *Halocynthia aurantium*

<220>

<221> PEPTIDE

<222> (1)

<223> 18mer of halocydin

<400> 1

Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala Lys Gly Val
1 5 10 15

Leu Ala

<210> 2

<211> 15

<212> PRT

<213> *Halocynthia aurantium*

<220>

<221> PEPTIDE

<222> (1)

<223> 15mer of halocydin

<400> 2

Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala Lys Gly
1 5 10 15

<210> 3

<211> 17

<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(17)
<223> 17mer of Halocydin

<400> 3
Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala Lys Gly Val
1 5 10 15

Leu

<210> 4
<211> 16
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(16)
<223> 16mer of Halocydin

<400> 4
Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala Lys Gly Val
1 5 10 15

<210> 5
<211> 14
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(14)
<223> 14mer of Halocydin

<400> 5
Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala Lys
1 5 10

<210> 6
<211> 13
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(13)
<223> 13mer of Halocydin

<400> 6
Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala
1 5 10

<210> 7
<211> 12
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(12)
<223> 12mer of Halocydin

<400> 7
Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys
1 5 10

<210> 8
<211> 18
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(18)
<223> 18mer congener of Halocydin

<400> 8
Trp Leu Asn Ala Leu Leu Lys Lys Gly Leu Asn Cys Ala Lys Gly Val
1 5 10 15

Leu Ala

<210> 9
<211> 19
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(19)
<223> 19mer of Halocydin

<400> 9
Lys Trp Leu Asn Ala Leu Leu His His Gly Leu Asn Cys Ala Lys Gly
1 5 10 15

Val Leu Ala

<210> 10
<211> 19
<212> PRT
<213> Halocynthia aurantium

<220>
<221> PEPTIDE
<222> (1)..(19)
<223> 19mer congener of Halocydin

<400> 10
Lys Trp Leu Asn Ala Leu Leu Lys Lys Gly Leu Asn Cys Ala Lys Gly
1 5 10 15

Val Leu Ala

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR02/02195

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C07K 14/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7:C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korea Patent and Applications for Inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubMed, Delphion, NCBI Blast, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Jang W. S., et al. "Halocidin: a new antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium" FEBS Lett., Jun 19, 2002, Vol. 521(1-3): pages 81-86, See the whole document.	1-11
Y	Lee I. H., et al. "Dicynthaurin: an antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium" Biochim. Biophys. Acta., Aug. 15, 2001, Vol. 1527(3): pages 141-148, See the whole document.	1-11
Y	Azumi K., et al. "Halocytamines: novel antimicrobial tetrapeptide-like substances isolated from the hemocytes of the solitary ascidian Halocynthia roretzi" Biochemistry, Jan. 9, 1990, Vol. 29(1): pages 159-165, See the whole document.	1-11
A	Taylor S.W., et al. "Styelin D, an extensively modified antimicrobial peptide from ascidian hemocytes" J. Biol. Chem., Dec. 8, 2000, Vol 275(49): pages 38417-38426, See the abstract.	1-11
A	WO9820028A2 (Lehrer et al.), May 14, 1998, See the whole document.	1-11

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 AUGUST 2003 (25.08.2003)

Date of mailing of the international search report

26 AUGUST 2003 (26.08.2003)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

HAN, Hyung Mee

Telephone No. 82-42-481-5601



INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/KR02/02195

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9820028 A2	May 14, 1998	US 6040293 US 6010876	Mar. 21, 2000 Jan. 04, 2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.